In short
Clinical trials are studying 18F-Fludarabine in people with newly diagnosed primary central nervous system lymphoma. These studies aim to see how well PET/MR imaging can measure tumor uptake and compare it with healthy tissue. The main focus is on imaging findings in patients who have not yet had surgery, radiotherapy, or chemotherapy.
Key points
- Clinical trials of 18F-Fludarabine are focused on imaging newly diagnosed primary central nervous system lymphoma. The main study is a Phase 1, interventional pilot trial in 16 patients who had not yet received surgery, radiotherapy, or chemotherapy. Researchers are using PET/MR imaging to study how the tracer is distributed in the brain and how much tumor tissue takes it up. The key endpoint is standardized uptake value, or SUV, measured in tumor lesions and compared with healthy tissue. The trial was completed and aimed to help characterize the imaging pattern of this disease.
Trial overview
The clinical trial in the source data studied 18F-Fludarabine PET/MR imaging in people with newly diagnosed primary central nervous system lymphoma. The purpose was to characterize the cerebral distribution of the tracer and its uptake in the tumor before any surgery, chemotherapy, or radiotherapy.
Who was studied
The study included patients with newly diagnosed primary CNS lymphoma who had not yet received surgery, radiotherapy, or chemotherapy. This means the trial focused on people at the start of their cancer care, before treatment could change the scan results.
The condition under study was primary central nervous system lymphoma, a lymphoma that starts in the brain or spinal cord area. The trial was designed as an interventional study, meaning researchers actively used the imaging procedure and then measured the results.
What was measured
The main outcome was the standardized measurement of tumor uptake, also called standardized uptake value (SUV). SUV is a number that shows how much tracer a tissue absorbs on imaging.
Researchers compared SUV in tumor lesions with SUV in healthy tissue on PET images that were superimposed on MRI images. This comparison helped show whether the tracer gathered more in the lymphoma than in normal brain tissue.
Imaging method used
The study used PET/MR imaging, which combines positron emission tomography (PET) and magnetic resonance imaging (MRI). PET shows where the tracer goes in the body, while MRI gives detailed pictures of the brain and nearby tissues.
The trial also used gadoteric acid as an imaging drug listed in the intervention section. The source data do not provide more detail about how it was used, so the main focus of the study remains the 18F-Fludarabine PET/MR scan.
Trial status and size
The study was a Phase 1 trial and was completed. It enrolled 16 participants, which is a small number typical of an early pilot study.
Because this was a pilot study, the main goal was to learn whether the imaging approach could describe tumor uptake and brain distribution in this patient group. The source data do not report treatment benefit, because the trial focused on imaging measurements rather than therapy.